MMSc

Genialis and Pancreatic Cancer Action Network (PanCAN) Partner to Progress KRAS Diagnostics

Retrieved on: 
星期五, 五月 31, 2024
Software, Research, General Health, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Clinical Trials, Science, Other Science, Health, Partnership, RAS, Patient, Progression-free survival, DNA, AACR, Doctor of Philosophy, Disease, Artificial intelligence, Histology, Cancer, Pancreatic cancer, AUROC, MMSc, Pancreatic Cancer Action Network, Biomarker, ASCO, Poster, RNA, Society, Physician, Survival rate, Receiver, Medicine, Annual general meeting

Genialis , the RNA-biomarker company, today announced a new partnership with the Pancreatic Cancer Action Network (PanCAN) to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced a new partnership with the Pancreatic Cancer Action Network (PanCAN) to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.
  • Overactivation of KRAS is implicated in up to 95 percent of pancreatic cancers, predominantly G12D, for which there are no approved drugs.
  • Genialis krasID is a biologically complex RNA-based biomarker panel predictive of response and benefit of KRAS inhibitor therapies and is designed to work across histologies.
  • “Pancreatic cancer is a tough disease with few treatment options, and currently the 5-year survival rate is 13 percent.

Wolters Kluwer UpToDate Awarded ACCME Accreditation With Commendation

Retrieved on: 
星期四, 五月 30, 2024
Technology, Health Technology, Software, Other Health, Other Education, Continuing, Training, General Health, Health, Education, Wolters Kluwer, Accreditation Council, Learning, Accreditation, CDS, UpToDate, Database, Research, Human, ACCME, MMSc, CME, Physician, Publishing, Continuing medical education, Nursing

Wolters Kluwer Health today announced that its clinical decision support (CDS) solution UpToDate ® has been awarded accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME®).

Key Points: 
  • Wolters Kluwer Health today announced that its clinical decision support (CDS) solution UpToDate ® has been awarded accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME®).
  • This is the fourth time UpToDate has been awarded accreditation with commendation since its initial accreditation.
  • According to Graham McMahon, MD, MMSc, President and CEO of ACCME, “UpToDate has been reviewed by the Accreditation Council for Continuing Medical Education and awarded accreditation with commendation for 6 years as a provider of continuing medical education (CME) for physicians.
  • Accreditation in the ACCME System seeks to assure the medical community and the public that UpToDate delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence.”
    For more information about Wolters Kluwer, please visit: www.wolterskluwer.com .

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

Retrieved on: 
星期二, 五月 14, 2024
Sickle cell disease, Grady Memorial Hospital, EHA, Harvard Medical School, Hospital, Central European, Hereditary spherocytosis, Winship Cancer Institute, Abstract, University Medical Center, MMSc, All but dissertation, AGIO, American University of Beirut, Launch, Disease, Anemia, Thalassemia, Hematology, Utrecht University, University, Hydroxycarbamide, University Medical Center Utrecht, Oncology, Iron overload, American University, Pharmaceutical industry

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that data from its programs will be presented at the European Hematology Association 2024 (EHA2024) Hybrid Congress, to be held June 13-16, 2024, in Madrid, Spain.

Key Points: 
  • Additional presentations will highlight data across Agios’ pipeline in rare blood disorders, including sickle cell disease and pyruvate kinase deficiency.
  • In total, seven abstracts led by Agios and external collaborators will be presented or published.
  • The accepted abstracts are listed below and are available online on the EHA congress website at www.ehaweb.org.
  • Data from the global Phase 3 ENERGIZE study of mitapivat in alpha- or beta- non-transfusion-dependent thalassemia.

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Sepsis, Patient, NAB, Retinal pigment epithelium, Bile, RAMP, Toxicity, ECOG, Febrile neutropenia, Verastem Oncology, Septic shock, BID, Clinical trial, Male, EDT, Avutometinib, Disease, Safety, Skin infection, Cancer, Pancreatic cancer, MMSc, Metastasis, ASCO, Anemia, Șaeș, Society, Eastern Cooperative Oncology Group, Mutation, Pulmonary embolism, Pneumoperitoneum, Webcast, BIW, Vomiting, DLT, Medicine, Annual general meeting, Phosphorus

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.
  • We continue to progress the study evaluating other dose and schedule regimens to determine the recommended Phase 2 dose in the trial,” said John Hayslip, M.D., chief medical officer of Verastem Oncology.
  • “We look forward to Verastem presenting their initial data from the Phase 1b/2a trial of avutometinib and defactinib in combination with standard care gemcitabine and Nab-paclitaxel in previously untreated metastatic pancreatic cancer at ASCO.
  • Verastem will hold an investor conference call and webcast on Friday, May 24 at 8:00 am EDT, to discuss these data.

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Retrieved on: 
星期四, 五月 9, 2024
SNF, FOLFIRINOX, DOI, Blood, Pancreatic cancer, Poster, TILS, Immunotherapy, TSX, PR, MD, Tumor microenvironment, AB, ONC, Roche, PDAC, Cancer, Patient, Pancreatic Cancer Action Network, AIO, Medicine, SWI, MMSc, Ethics, PD, Therapy, SAN, Anal cancer, TME, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.

Key Points: 
  • This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).
  • It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
星期二, 三月 12, 2024
Administration, Plasma, Kidney disease, ECTS, Massachusetts General Hospital, Pyrophosphate, PD, ASN, Partnership, Pharmacokinetics, Calciphylaxis, G&A, PROPEL, Doctor of Philosophy, Chemistry, Investment, PXE, Society, Pathology, Therapy, Safety, Research and development, ESKD, ENPP1, MMSc, Natural history, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JOSEPH F. MEROLA, MD, MMSc, FAAD, FACR

Retrieved on: 
星期四, 四月 4, 2024
Cone Health Women's Hospital, Internal medicine, Patient, Skin, FAAD, Connective tissue, DSM-IV codes, Education, ASA, MDS, MMSc, Mass, Harvard Medical School, Associate, National Psoriasis Foundation, Psoriatic arthritis, Hospital, Public health, Atopic dermatitis, Dermatomyositis, Lupus, American Academy, Assessment, Management

NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
  • Distinguished Chair in Dermatology and is Professor at the Peter O'Donnell Jr. School of Public Health.
  • "We are proud to announce the addition of Dr. Joseph Merola to ASA's Board of Directors.
  • He was recently elected to the Board of the American Academy of Dermatology.

THE PANCREATIC CANCER ACTION NETWORK NAMES ANNA BERKENBLIT, MD, MMSc AS FIRST-EVER CHIEF SCIENTIFIC AND MEDICAL OFFICER

Retrieved on: 
星期二, 四月 2, 2024
Harvard Medical School, Health, Growth, ImmunoGen, Patient, Research, MD, MBA, Outline of health sciences, Pancreatic Cancer Action Network, Pancreatic cancer, Biomedicine, FDA, MMSc

LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
  • "And I'm really excited to join PanCAN to build on our scientific and medical initiatives to take PanCAN to the next phase of growth."
  • "We are honored to welcome Dr. Berkenblit to PanCAN as our first-ever chief scientific and medical officer.
  • She will serve as a thought leader for us in the pancreatic cancer scientific and medical community working with our external advisors and stakeholders," said Fleshman.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
星期日, 三月 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)

Retrieved on: 
星期一, 十二月 11, 2023
MMSc, Hospital, AKI, Division, Cone Health Women's Hospital, Mortality, Neutropenia, SCR, Society, Odds ratio, Observational study, Acute kidney injury, Transaminase, MPH, Patient, Harvard Medical School, Nursing

West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.

Key Points: 
  • West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.
  • Among the 708 patients with HDMTX-AKI, 209 (29.5%) were treated with glucarpidase and 499 (70.5%) were not.
  • Treatment with glucarpidase was associated with a 2.41-fold higher adjusted odds of kidney recovery at hospital discharge (95% CI, 1.33–4.37) compared to those not treated with glucarpidase.
  • “This is the largest study to date of HDMTX-AKI,” said study author Dr. Shruti Gupta, MD, MPH, Director of Onconephrology in the Division of Renal Medicine, Brigham and Women's Hospital.